StoneX Group Inc. Purchases New Shares in AngioDynamics, Inc. (NASDAQ:ANGO)

StoneX Group Inc. acquired a new position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 107,083 shares of the medical instruments supplier’s stock, valued at approximately $981,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. SBI Securities Co. Ltd. acquired a new stake in shares of AngioDynamics in the fourth quarter worth approximately $28,000. BNP Paribas Financial Markets boosted its stake in AngioDynamics by 110.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 159,391 shares of the medical instruments supplier’s stock worth $1,240,000 after purchasing an additional 83,622 shares during the last quarter. State Street Corp boosted its stake in AngioDynamics by 2.7% during the 3rd quarter. State Street Corp now owns 810,372 shares of the medical instruments supplier’s stock worth $6,305,000 after purchasing an additional 21,218 shares during the last quarter. Barclays PLC grew its holdings in shares of AngioDynamics by 81.0% during the third quarter. Barclays PLC now owns 83,582 shares of the medical instruments supplier’s stock worth $651,000 after buying an additional 37,394 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of AngioDynamics by 28.7% in the third quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier’s stock valued at $4,304,000 after buying an additional 123,271 shares during the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $12.31, for a total value of $49,978.60. Following the transaction, the senior vice president now directly owns 41,817 shares in the company, valued at approximately $514,767.27. This represents a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 5.40% of the company’s stock.

AngioDynamics Stock Performance

NASDAQ ANGO opened at $9.66 on Wednesday. The stock’s fifty day moving average is $10.30 and its two-hundred day moving average is $8.84. The firm has a market capitalization of $390.90 million, a P/E ratio of -1.72 and a beta of 0.56. AngioDynamics, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $13.50.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The firm had revenue of $72.90 million during the quarter, compared to analyst estimates of $70.93 million. During the same quarter in the prior year, the firm posted ($0.05) earnings per share. AngioDynamics’s quarterly revenue was down .1% on a year-over-year basis. As a group, sell-side analysts forecast that AngioDynamics, Inc. will post -0.37 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright upped their price objective on shares of AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, January 10th.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.